Alkem Laboratories Limited has informed the Exchange about Investor Presentation
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alkem Laboratories reported record high EBITDA of ₹30,052 million for FY26, up 19.6% YoY with margins expanding to 20.4% from 19.4% in FY25. Total revenue grew 13.5% YoY to ₹147,123 million. Q4FY26 also showed strong performance with revenue of ₹36,033 million (14.6% growth) and EBITDA up 32.2% YoY to ₹5,174 million. Domestic business grew 9.7% YoY to ₹98,514 million while international business accelerated with 22.5% growth to ₹46,810 million, driven by 26.2% US sales growth in Q4. The company outperformed the Indian Pharmaceutical Market across acute and chronic segments. Management attributed margin expansion to improved business mix, operating leverage and cost discipline, and expects healthy growth in FY27 from chronic therapies and differentiated international launch pipeline.
The strong results with record EBITDA and margin expansion are positive signals for shareholders, indicating operational efficiency improvements. The accelerating international business and outperformance in key therapy segments strengthen the growth outlook, though investors should note the one-time exceptional items impacting net profit.